Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization

Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial

(2021) Michael E. Nassif et al.   CIRCULATION

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

(2021) Stefan D. Anker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF

(2021) Juan Antonio Requena-Ibáñez et al.   JACC-Heart Failure

Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition

(2020) Rhys Williams et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

(2020) Matthew Griffin et al.   CIRCULATION

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes

(2020) Apostolos Tsapas et al.   ANNALS OF INTERNAL MEDICINE

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy

(2020) Chintan V. Dave et al.   CIRCULATION

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

(2020) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure

(2020) Carlos G. Santos-Gallego et al.   JACC-Cardiovascular Imaging

An update on the safety of SGLT2 inhibitors

(2019) André J Scheen   Expert Opinion On Drug Safety

Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study

(2019) Rozalina G. McCoy et al.   Diabetes Technology & Therapeutics

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

The Cost of Diabetes Care—An Elephant in the Room

(2018) Matthew C. Riddle et al.   DIABETES CARE

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

(2018) Mikhail Kosiborod et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Plasma Glucose Level as a Predictor of In-Hospital Mortality in Patients at an Emergency Room: A Retrospective Cohort Study

(2018) Ryo Yoshinaga et al.   DIABETES CARE

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

(2017) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beyond Bathrooms — Meeting the Health Needs of Transgender People

(2016) Mark A. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Validating the 8 CPCSSN Case Definitions for Chronic Disease Surveillance in a Primary Care Database of Electronic Health Records

(2014) T. Williamson et al.   ANNALS OF FAMILY MEDICINE

Generalized propensity score for estimating the average treatment effect of multiple treatments

(2011) Ping Feng et al.   STATISTICS IN MEDICINE

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

(2009) Peter C. Austin   STATISTICS IN MEDICINE